The utility of quantitative computed tomography in cohort studies of chronic obstructive pulmonary disease: a narrative review

Qi Dai\textsuperscript{1,2}, Xiaoxiao Zhu\textsuperscript{3}, Jingfeng Zhang\textsuperscript{2}, Zhaoxing Dong\textsuperscript{3}, Eugenio Pompeo\textsuperscript{4}, Jianjun Zheng\textsuperscript{2}, Jingyun Shi\textsuperscript{1,5}

\textsuperscript{1}School of Medicine, Tongji University, Shanghai, China; \textsuperscript{2}Department of Radiology, Ningbo No.2 Hospital, Ningbo, China; \textsuperscript{3}Department of Respiratory and Critical Care Medicine, Ningbo No.2 Hospital, Ningbo, China; \textsuperscript{4}Department of Thoracic Surgery, Policlinico Tor Vergata University, Rome, Italy; \textsuperscript{5}Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

\textbf{Contributions:} (I) Conception and design: J Zheng, J Shi; (II) Administrative support: J Zheng, J Shi; (III) Provision of study materials or patients: Q Dai, X Zhu; (IV) Collection and assembly of data: Q Dai, J Zhang; (V) Data analysis and interpretation: Q Dai, J Zhang, Z Dong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

\textbf{Correspondence to:} Jianjun Zheng, Bachelor. Department of Radiology, Ningbo No.2 Hospital, 41 Xibei Road, Ningbo 315010, China. Email: zhengjianjun@ucas.ac.cn; Jingyun Shi, MD. School of Medicine, Tongji University, 1239 Siping Road, Shanghai 200092, China; Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, Shanghai 200092, China. Email: shijingyun89179@126.com.

\textbf{Background and Objective:} Chronic obstructive pulmonary disease (COPD) is a significant contributor to global morbidity and mortality. Quantitative computed tomography (QCT), a non-invasive imaging modality, offers the potential to assess lung structure and function in COPD patients. Amidst the coronavirus disease 2019 (COVID-19) pandemic, chest computed tomography (CT) scans have emerged as a viable alternative for assessing pulmonary function (e.g., spirometry), minimizing the risk of aerosolized virus transmission. However, the clinical application of QCT measurements is not yet widespread enough, necessitating broader validation to determine its usefulness in COPD management.

\textbf{Methods:} We conducted a search in the PubMed database in English from January 1, 2013 to April 20, 2023, using keywords and controlled vocabulary related to QCT, COPD, and cohort studies.

\textbf{Key Content and Findings:} Existing studies have demonstrated the potential of QCT in providing valuable information on lung volume, airway geometry, airway wall thickness, emphysema, and lung tissue density in COPD patients. Moreover, QCT values have shown robust correlations with pulmonary function tests, and can predict exacerbation risk and mortality in patients with COPD. QCT can even discern COPD subtypes based on phenotypic characteristics such as emphysema predominance, supporting targeted management and interventions.

\textbf{Conclusions:} QCT has shown promise in cohort studies related to COPD, since it can provide critical insights into the pathogenesis and progression of the disease. Further research is necessary to determine the clinical significance of QCT measurements for COPD management.

\textbf{Keywords:} Quantitative computed tomography (QCT); chronic obstructive pulmonary disease (COPD); cohort study

Submitted Sep 08, 2023. Accepted for publication Sep 27, 2023. Published online Oct 27, 2023.
doi: 10.21037/jtd-23-1421

\textbf{View this article at:} https://dx.doi.org/10.21037/jtd-23-1421
Introduction

Chronic obstructive pulmonary disease (COPD) represents a significant global health issue, due to its high morbidity and mortality rates, and it is projected to rank as the third leading cause of death globally by 2030 (1). Smoking is strongly linked to the incidence of COPD, particularly in Asian regions like China where high tobacco consumption contributes to a higher prevalence. In China, more than 13% of people over the age of 40 years develop COPD, and the total number of patients is estimated to be approximately 99.9 million in 2018 (2). The disease is characterized by incompletely reversible airflow obstruction and can affect different levels of the respiratory system with heterogeneous clinical presentations (3). Although spirometry remains the traditional method of COPD diagnosis and staging, imaging modalities such as quantitative computed tomography (QCT) may offer more comprehensive diagnostic and therapeutic insights. Especially during the coronavirus disease 2019 (COVID-19) pandemic, pulmonary function test procedures should be used with caution, due to the risk of aerosolized virus transmission (4). As a result, innovative diagnostic tools like QCT have gained popularity. QCT can safely evaluate COPD severity, including emphysema and airway obstruction, offering potential as a preliminary screening tool and guide for personalized COPD treatment (5).

The development of QCT enables rapid anatomical localization and quantitative detection of morphological and functional changes in the respiratory system, offering a globally standardized measurement method and advancing our understanding of the disease pathogenesis and prognosis (6-8). Identifying population at risk and effective biomarkers for disease outcome prediction represent important challenges in COPD management. In particular, cohort studies can be implemented to analyze lung anatomical changes in patients using computed tomography (CT) indicators, improve early COPD recognition, increase awareness of clinical phenotype, identify appropriate screening methods, and investigate treatment effectiveness and prognosis. CT indicators are frequently utilized as biomarkers for personalized treatment and prognosis assessment (9). In this paper, we provide a comprehensive summary of the significant findings of QCT in large-scale cohort studies of COPD and related researches conducted in the past decade, with particular emphasis on potential future directions for QCT research encompassing image features related to COPD progression and clinical outcomes. This article is presented in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1421/rc).

Methods

Publications in the PubMed database over the past few decades have provided comprehensive descriptions of the contribution of QCT in COPD cohort studies. A total of 1,181 papers were retrieved that had been published between January 1, 2013, and April 20, 2023, with an optimized search strategy. Rigorous scrutiny of inclusion criteria resulted in the selection of 74 publications that align closely with the topic of COPD cohort studies and QCT contribution. Additional articles were discovered by conducting a thorough review of the reference lists in relevant publications. Further details on this method are provided in Table 1.

Overview of COPD cohort studies

In recent decades, cohort studies using clinical questionnaires, spirometry, chest QCT, and longitudinal follow-up, have been conducted. Internationally significant COPD cohort studies, including COPD Genetic Epidemiology (COPDGene) (10), Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points (ECLIPSE) (11), and Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) (12) have been conducted in recent years. In China, Investigation of the Clinical, Radiological and Biological Factors, Humanistic and Healthcare Utilization Burden Associated with Disease Progression, Phenotypes, and Endotypes of COPD (COMPASS) (13) is one of the largest research projects on COPD. Each cohort study has specific distinct objectives and observation indexes (Table 2). COPDGene aims to identify susceptibility genes and key factors, and establish a novel COPD classification system based on clinical data, genetic epidemiology, and CT imaging data of smokers or former smokers in the United States. ECLIPSE, a longitudinal observational study, was carried out across 46 clinical centers located in Europe and the United States to identify genetic factors and biomarkers for COPD progression by defining clinically relevant subtypes and predicting disease progression. SPIROMICS is a multicenter longitudinal study supported by clinical drug trials to discern genetic factors and biomarkers linked to clinical COPD subtypes and to forecast disease progression. Furthermore, SPIROMICS classifies COPD subtypes and...
Table 1 The search strategy summary

<table>
<thead>
<tr>
<th>Items</th>
<th>Specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of search</td>
<td>April 20, 2023</td>
</tr>
<tr>
<td>Databases and other sources</td>
<td>PubMed (NLM)</td>
</tr>
<tr>
<td>Search terms used</td>
<td>(“Tomography, X-Ray Computed”(MeSH) OR “Tomography, Spiral Computed”(MeSH) OR “Tomography, X-Ray Computed”(Title/Abstract) OR “CT scan”(Title/Abstract) OR “Computed tomography”(Title/Abstract) OR “QCT”(Title/Abstract) OR “Quantitative computed tomography”(Title/Abstract) AND (“Cohort studies”(MeSH) OR “Prospective studies”(MeSH) OR “Longitudinal studies”(MeSH) OR “Observational studies”(MeSH) OR “Follow-up studies”(MeSH) OR “Cohort studies”(Title/Abstract)) AND (“Pulmonary disease, chronic obstructive”(MeSH) OR “Chronic bronchitis”(MeSH) OR “Emphysema”(MeSH) OR “COPD”(Title/Abstract) OR “Chronic obstructive pulmonary disease”(Title/Abstract))</td>
</tr>
<tr>
<td>Timeframe</td>
<td>January 1, 2013–April 20, 2023</td>
</tr>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>Inclusion criteria</td>
</tr>
<tr>
<td></td>
<td>• Population: including patients diagnosed with COPD</td>
</tr>
<tr>
<td></td>
<td>• Study design: cohort studies with &gt;2-year follow-up</td>
</tr>
<tr>
<td></td>
<td>• CT application: quantitative CT for COPD, such as lung structure, airway diameter, lung function, etc.</td>
</tr>
<tr>
<td></td>
<td>• Outcome measurement: quantifiable data regarding CT results, such as the extent of lung lesions, progression of pathological changes, etc.</td>
</tr>
<tr>
<td></td>
<td>• Publication date: prioritize recent studies to include the latest discoveries and technologies</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>• Study design: includes fewer than 500 individuals, or don’t meet the cohort study requirements</td>
</tr>
<tr>
<td></td>
<td>• No COPD diagnosis: without patients clearly diagnosed with COPD</td>
</tr>
<tr>
<td></td>
<td>• No involvement of QCT application: don’t involve QCT applications for COPD</td>
</tr>
<tr>
<td></td>
<td>• Incomplete data: insufficient data and information to support objectives</td>
</tr>
<tr>
<td></td>
<td>• Publication quality: published in non-authoritative and low credibility journals</td>
</tr>
<tr>
<td>Selection process</td>
<td>The selection of literature was conducted by Qi Dai, Xiaoxiao Zhu. All authors collaborated in establishing inclusion and exclusion criteria, reaching a consensus on the finalized list of literature</td>
</tr>
<tr>
<td>Any additional considerations, if applicable</td>
<td>Newly published papers with robust study designs and large sample sizes are preferred for citation among similar content</td>
</tr>
</tbody>
</table>

NLM, National Library of Medicine; MeSH, Medical Subject Headings; CT, computed tomography; QCT, quantitative computed tomography; COPD, chronic obstructive pulmonary disease.

predicts biomarkers related to treatment benefits, based on the extent of patients’ response to specific treatments. COMPASS aims to determine the factors associated with the progression of COPD, as well as its phenotypes and endotypes in China by analyzing clinical, radiological, and biological factors by 41 clinical centers in China.

**CT quantification of emphysema**

Emphysema is a chronic lung disease characterized by permanent dilation of terminal bronchioles, destruction of alveolar walls and bronchioles, that primarily occurs due to smoking. The use of CT scans to define the emphysema region via Hounsfield units (HU) lower than -950 HU is a widely accepted threshold (14). The CT threshold utilized to quantify lung low-density areas (LLA) is useful for providing objective measures of emphysema severity (Figure 1). The SPIROMICS study (15) has shown that a significant proportion of emphysema can be detected on chest CT scans of smokers with no airflow limitations, emphasizing...
Table 2 Basic information of 4 different COPD cohort studies

<table>
<thead>
<tr>
<th>Category</th>
<th>COPDGene</th>
<th>ECLIPSE</th>
<th>SPIROMICS</th>
<th>COMPASS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area</td>
<td>United States</td>
<td>Europe, North America</td>
<td>United States</td>
<td>China</td>
</tr>
<tr>
<td>Centers</td>
<td>21</td>
<td>12</td>
<td>6</td>
<td>41</td>
</tr>
<tr>
<td>Participants</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>45–80</td>
<td>40–75</td>
<td>40–80</td>
<td>40–80</td>
</tr>
<tr>
<td>Male (%)</td>
<td>51</td>
<td>64</td>
<td>52</td>
<td>N/A</td>
</tr>
<tr>
<td>Female (%)</td>
<td>49</td>
<td>36</td>
<td>48</td>
<td>N/A</td>
</tr>
<tr>
<td>Non-smoking</td>
<td>N/A</td>
<td>245</td>
<td>200</td>
<td>120</td>
</tr>
<tr>
<td>Smoking</td>
<td>N/A</td>
<td>337</td>
<td>900</td>
<td>N/A</td>
</tr>
<tr>
<td>PRISm</td>
<td>1,323</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>GOLD 0</td>
<td>4,378</td>
<td>N/A</td>
<td>N/A</td>
<td>180</td>
</tr>
<tr>
<td>GOLD I</td>
<td>788</td>
<td>N/A</td>
<td>1,500 (I &amp; II)</td>
<td>700</td>
</tr>
<tr>
<td>GOLD II</td>
<td>1,925</td>
<td>915</td>
<td>700</td>
<td></td>
</tr>
<tr>
<td>GOLD III</td>
<td>1,164</td>
<td>861</td>
<td>600 (III &amp; IV)</td>
<td>200</td>
</tr>
<tr>
<td>GOLD IV</td>
<td>606</td>
<td>278</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Total</td>
<td>10,198</td>
<td>2,746</td>
<td>3,200</td>
<td>2,000</td>
</tr>
</tbody>
</table>

Evaluation features

- Symptom questionnaire: √
- Quality of life score: √
- Biphasic chest CT: √
- Spirometry: √
- DLCO: √
- IOS: x
- 6-minute walking test: √
- Sputum and blood biomarkers: √
- Genome sequencing: √
- Lung microbiota: x

Follow-up: Long-term since 2008 3-year-long since 2008 3-year-long since 2010 2.5-year-long since 2019

COPD, chronic obstructive pulmonary disease; COPDGene, COPD Genetic Epidemiology; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points; SPIROMICS, Subpopulations and Intermediate Outcomes in COPD Study; COMPASS, Investigation of the Clinical, Radiological and Biological Factors, Humanistic and Healthcare Utilization Burden Associated with Disease Progression, Phenotypes, and Endotypes of COPD; N/A, not applicable; PRISm, Preserved Ratio Impaired Spirometry; GOLD, Global Initiative for Chronic Obstructive Lung Disease; CT, computed tomography; DLCO, diffusion capacity of carbon monoxide; IOS, Impulse Oscillometry System.

that the impact of smoking can be severely underestimated by lung function tests alone. A study examining 4,542 participants from the COPDGene cohort demonstrated that emphysema severity was associated with both impaired lung capacity and poor airflow limitation, as indicated by markedly. The ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) and FEV1 (correlation coefficient r=20.76 and 20.67 respectively) (16).
A recent multicenter study (17) involving 4,211 participants revealed that emphysema progression in smokers could be measured accurately via the adjusted CT lung density (ALD) technique over a 5-year duration, thus highlighting the limited utility of measuring emphysema progression based on FEV1, which is less than 10% accurate compared to CT imaging. Emphysema is associated with a multidimensional score that predicts mortality risk in patients with COPD based on body mass index (BMI), presence of airflow obstruction, dyspnea, and exercise tolerance, known as the BODE index (18). Importantly, emphysema has a more profound effect on BODE score than respiratory illnesses (19,20). Although yielding potential limitations regarding sensitivity to longitudinal follow-up changes, visual evaluation remains the CT evaluation standard for emphysema. Using deep learning algorithms, Oh et al. (21) analyzed sequential chest CT scans of smokers and graded emphysema severity. Results of this study showed that an increase in emphysema score was associated with severe lung dysfunction and elevated mortality risk. Moreover, difference in CT equipment and scanning protocols have shown to affect the accuracy of prognostic evaluation.

There are ethnic disparities in emphysema. Hansel et al. (22) conducted a study involving 1,063 patients with moderate and severe COPD, which revealed that lung function impairment, airway wall thickness, and gas retention among African Americans and non-Hispanic Whites were similar, with only minimal emphysema detected by CT scans. A survey of 515 Black urbanites in a SPIROMICS cohort demonstrated a relatively high

![Figure 1](image-url) Quantitative and 3D visualizations of low attenuation area % in patients with varying degrees of emphysema. MPR lung images are shown for 3 patients: 1 with mild emphysema [low attenuation area % (LAA%) =9.62], 1 with moderate emphysema (LAA% =38.59), and 1 with severe emphysema (LAA% =68.61). Furthermore, 3D lung images were reconstructed using CT technology, providing more intuitive and visual representations of the extent of emphysema. The 3 reconstructed 3D images correspond to the 3 emphysema categories, respectively. LAA, low attenuation area; MPR, multi-planar reconstruction; 3D, 3-dimensional; CT, computed tomography.
incidence of emphysema in segregated residents, as well as a significantly frequent occurrence of severe exacerbations of COPD (23). There are also gender differences in development of emphysema. Female patients with early onset COPD have a significantly lower smoking burden than men; however, their emphysema degrees are generally similar to those of men. This finding suggests that women might be more susceptible to smoking-related lung damage (24).

The recent study has identified differences in the prognosis of patients with varying emphysema subtypes. CT scans performed on 399 patients from two distinct observational groups revealed that patients with moderate-to-severe centrilobular emphysema (CLE) exhibited faster declines in diffusion capacity and higher long-term mortality rates. These results suggest that CLE and paraseptal emphysema (PSE) may have varying clinical and physiological effects on patients (25).

Other factors, such as CT scan parameters, can affect the quantification of emphysema by CT value. CT value can be converted to calculate lung mass using the following formula: lung mass (g) = (HU + 1.024/1.024) × voxel volume × voxel quantity. Lung quality can supplement pulmonary air content in COPD quantitative CT imaging. A 5-year follow-up study of 1,623 cases from the COPDGene cohort identified that patients with early-onset COPD had higher lung mass compared to smokers with normal lung function and patients with intermediate and advanced COPD. This finding indicates a biphasic process of lung mass development throughout the course of COPD, with persistence of inflammation in early stages leading to increased lung mass followed by predominant tissue destruction and reduced lung mass (26,27).

**CT quantification of abnormal airway**

For the diagnosis and management of COPD, using quantitative CT imaging of the airways necessitates standardized technical criteria. Furthermore, high-quality evidence is required to establish clinical benefits for management guided by airway quantitative CT imaging (28). COPD airflow resistance occurs mainly in small airways with diameters of less than 2 mm, ranging from grade 4 to grade 12, which are characterized by inflammation. The gradual airway wall thickening and lumen narrowing in COPD result from hypertrophied mucus glands, smooth muscle cell proliferation, and fibrosis of the airway wall. Although The processes of inflammation and remodeling were previously thought to occur exclusively in small airways, recent research has shown that these processes can also occur simultaneously in larger, segmental, and subsegmental airways (29,30).

Several indices may be utilized for estimating airway size, with the proximal airway being directly observed and measured through CT technology. Utilizing threshold-based analysis and the half-height full-width algorithm, the airway tree could be segmented and the airway wall diameter line can be quantified after a 3-dimensional (3D) reconstruction of the tracheobronchial tree (31). Bronchial wall thickness, tracheal lumen area, tracheal lumen diameter, wall area percent (WA%), and internal perimeter (Pi) are among the direct quantitative indices of the airway. A significant correlation with histological measurements of the airway (32) was found in relation to these measurements. Due to their perpendicular position to the axial orientation and minimal exposure to heartbeats, the bronchus and its branches in the upper lobe of the right lung are preferred for airway measurement. The WA% can be calculated using the following formula: WA% = (total airway area – airway lumen area)/total airway area × 100. To enable inter-individual comparison, the standardized bronchial wall thickness is frequently represented by the square root of airway wall area. Pi10 and Pi15 are reference values for small airway disease assessment, representing the square root of theoretical airway wall area with an inner circumference of 10 and 15 mm, respectively (33).

Continuous development in CT technology has transformed airway measurement from 2-dimensional (2D) to 3D, resolving the errors caused by the non-vertical geometric construction between the measured bronchial and the 2D cross section. With the aid of specialized software, automatic measurement can be conducted at positions perpendicular to the airways for those bronchial segments. Measured airway levels can extend to level 5 or 6, allowing for a more realistic depiction of small COPD airway changes (34,35). A prospective COPD cohort study routine CT scan concluded that standardization of Pi10 airway wall thickness can potentially serve as an imaging biomarker for lung function decline, increased mortality risk, and disease severity (36).

The COPDGene study (18) findings revealed that CT airway quantitative indices are significantly and independently related to respiratory quality of life based on St. George’s Respiratory Questionnaire (SGRQ) assessment. Following standardized treatment, airway wall thickness, WA%, and Pi10 values in the lung segment increased by 1 unit, whereas corresponding SGRQ scores were elevated by 1.9, 1.5, and 2.8 units, respectively. The measured value of airway
wall thickness is correlated with chronic bronchitis (37), and normal or abnormal reactions to bronchodilator use (38,39), which can predict airway reactivity. With the advancement of artificial intelligence, unsupervised machine learning offers a peripheral bronchial identification accuracy of up to 96% in CT, enabling fully automated tube wall thickness measurement and high-throughput analysis (40). Analysis of CT scans evaluating central airway wall area, lumen and total bronchial area in 5,179 smokers and 92 nonsmoking individuals in the COPDGene cohort revealed an increase in WA% due to the combined effect of airway reduction and wall thickening (41). The SPIROMICS cohort study also confirmed that the duct wall area of grade 1–6 decreased linearly as COPD severity increased (42). It is essential to acknowledge that although WA% has a close relationship with respiratory system function and diseases. The provided information is insufficient to comprehensively understand the relative remodeling happening within the airway wall and lumen. Moreover, the limited range of variation between normal and severe lung disease restricts its effectiveness in assessing longitudinal changes over time and treatment response (43).

Notable gender and individual differences have been observed in natural airway anatomy. Analysis of CT images from the multi-center COPDGene cohort found that female smokers had a higher WA% than male smokers. However, these individuals exhibited smaller dimensions in terms of lumen area, inner diameter, and airway thickness when compared to anatomically similar airways (44). Those who had previous incidents of asthma during childhood are more likely to have smaller airways, heightening their susceptibility to long-lasting airflow blockage in adulthood (45). Other studies have revealed a significant interdependence between airway diameter and lung parenchyma (46,47). Furthermore, there is an inverse correlation between the degree of emphysema and the size of the airway, particularly in COPD patients with a bronchitis phenotype. As the emphysema phenotype's severity increases, the change in airway diameter will gradually diminish, which partly explains why emphysema has low responsiveness to bronchodilators. Furthermore, airway collapse is common in smokers, especially in COPD patients, due to weakened tracheal cartilage or reduced wall elasticity. In a study of 8,830 COPDGene cohort cases (48) approximately 5% of smokers experienced airway collapse during exhalation, with a worsening quality of life and a higher likelihood of having acute respiratory disease.

CT quantification of air trapping

Air retention is an early CT sign of small airway disease. Since CT cannot directly display small airways, quantitative and indirect evaluation can be performed through dual-phase scanning during expiration and inspiration. The primary indexes of measurement are as follows: (I) the percentage of emphysema area in the total lung area during the expiratory phase with a lung density below −856 HU (LAA% −856); (II) the ratio of mean lung density during expiration to inspiration (E/I-ratio MLD); (III) the RVC, which stands for relative volume change in respiration, between −856 and −950 HU (i.e., the difference between the lung volume with an inspiratory phase lung density between −856 and −950 HU and the lung volume with an expiratory phase lung density between −856 and −950 HU); and (IV) air trapping index (ATI), the area of low attenuation where the density of the inspiratory and expiratory phases remains unchanged (Figure 2). Currently, the recommended ATI threshold is 60 HU. Air retention was associated with respiratory disease scales, such as dyspnea, breath-related quality of life, along with 6-minute walking distance (6MWD) (49). In another study, among 8,034 cases (50), 26.3% of smokers without airflow obstruction had an increased E/I ratio, which was associated with FEV1, SGRQ score, 6MWD, and BODE index.

Parameter response mapping (PRM) is the registration of inspiratory phase and expiratory phase CT image voxels. Each voxel consists of a pair of CT values sharing the same geometric space. The voxels are divided into three categories based on CT density threshold: (I) inspiratory phase ≤−950 HU and expiratory phase ≤−856 HU, representing the emphysema region marked in red on the image and recorded as PRM emphysema (PRMEmph); (II) inspiratory phase ≥−950 HU and expiratory phase ≤−856 HU, representing the small airway lesion area displayed in yellow on the image and recorded as PRM functional small airways disease (PRMfSAD); (III) inspiratory phase ≥−950 HU and expiratory phase ≥−856 HU, representing the normal area denoted in green on the image and recorded as PRMNorm. The results are displayed as graphs, and the percentage of each category is calculated to locate lesions in COPD patients locally (Figure 3). McDonough et al. (51) and Galbán et al. (52) confirmed that the narrowing and disappearance of small airways occur prior to the development of emphysema in the progression of COPD. PRM, as a biomarker to distinguish air retention caused by emphysema and small
Figure 2 Coronal gas retention threshold and quantitative results of fAT% in a GOLD stage II patient who had a functional air trapping rate of 34%. (A) The yellow area in the figure represents the lung regions with air trapping following full exhalation. (B) The pie chart shows the percentage of air trapping in each lobe and the entire lung upon complete exhalation. fAT, functional air trapping; GOLD, Global Initiative for Chronic Obstructive lung Disease.

Figure 3 fSAD probability map in the 2 patients. The PRM\textsuperscript{fSAD} shows the distribution of gas retention in the peripheral airways among these patients. Abnormality in the peripheral airways differed, with the percentage of low attenuation area in the left and right PRM\textsuperscript{fSAD} being 27% and 73%, respectively. EAtC-fAT, functional air trapping by EAtC; EAtC, emphysema air-trapping composite; PRM-fSAD/PRM\textsuperscript{fSAD}, PRM functional small airways disease; PRM, parameter response mapping; LAAExp, low attenuation area on expiration CT; HU, Hounsfield units; CT, computed tomography.

airway lesions, provides abundant imaging information for COPD phenotypic classification (53) and facilitates accurate assessment of the heterogeneity in the progression of COPD (43). In a study involving 1,508 participants from the COPDGene cohort, it was found that PRM\textsuperscript{fSAD} measured at baseline correlated with decreased FEV1 in both smokers without airflow blockages and patients in the early stages of the disease. PRM\textsuperscript{Emph} and PRM\textsuperscript{fSAD} demonstrated
links to altered lung function in smokers with more severe disease (54). Martinez et al. (55) found that PRM
increased by 2.7% every 10 years in the normal population, regardless of gender, age, smoking history, and asthma history. Every 1% increase in PRM would lead to a minimal increase of 9.4 mL in FVC and a decrease of approximately 0.15% in FEV1/FVC, consistent with the results obtained by Boudewijn et al. (56). Bhatt et al. (54) conducted a 5-year follow-up of 1,508 smokers and found that the increase of PRM was significantly correlated with the decrease of FEV1 in non-COPD smokers. Furthermore, both PRM and PRMEmp were correlated with the decrease of FEV1 in COPD patients; the correlation between PRM and weakened lung function was more significant among individuals diagnosed with mild-to-moderate COPD. Thus, PRM can be employed as supplementary information for FEV1 to evaluate the response to drug therapy in COPD patients, suggesting that PRM can be an effective tool for long-term assessment of COPD disease progression. Advances in artificial intelligence technology have allowed PRM to be based on machine learning classification models. This results in a stronger correlation with pulmonary function tests that enables better distinction between high-risk and normal COPD patients. Additionally, by determining the optimal FEV1% prediction value, this approach lays a foundation for redefining the diagnosis of high-risk COPD (57).

CT quantification of pulmonary vascular injury
Pathological pulmonary vascular remodeling is prevalent in COPD patients, and sometimes even observed in non-smokers with normal lung function. Quantitative evaluation of pulmonary vascular conditions through CT has implications for the study of COPD and changes in the cardiovascular system (58). Cross-sectional area percentage (%CSA) is a developing indicator for COPD evaluation. Specifically, %CSA <5 mm (i.e., the percentage of the sum of small blood vessels with a pulmonary vascular area <5 mm to the total lung area) and %CSA 5–10 mm (i.e., the percentage of the sum of small blood vessels with a pulmonary vascular area of 5–10 mm of the total lung area) are currently the most commonly used %CSA indicators (59,60). Wang et al. (61) suggested that QCT can evaluate the %CSA of pulmonary small vessels and predict the existence of COPD acute exacerbations and severity. Additionally, Takayanagi et al. (62) showed that despite the gradual progression of emphysema in COPD patients who quit smoking, there was no distinct trend of increase in %CSA <5 mm. Therefore, it can be inferred that smoking-induced COPD vascular remodeling is reversible to some extent.

Individuals diagnosed with COPD frequently exhibit mild-to-moderate pulmonary hypertension (63), characterized by changes in pulmonary great vessels, which are often imperceptible at this stage. The evaluation of COPD combined with pulmonary hypertension by measuring %CSA represents a valuable prospective approach. The possible physiological mechanism of this method encompasses 2 stages: (I) COPD patients experience pulmonary parenchyma destruction and excessive expansion of lung tissues, which cause compression and damage to peri-alveolar pulmonary small vessels, resulting in a decreased number of these vessels (64); and (II) factors such as smoking, inflammation, and hypoxia stimulate pulmonary vascular endothelial cells, leading to smooth muscle cell hypertrophy, fibroblast phenotype change, pulmonary vascular remodeling, tube wall thickening, lumen stenosis, and even occlusion (65). To assess the presence of severe pulmonary hypertension in COPD, Coste et al. (66) proposed a scoring method that combines arterial oxygen partial pressure, bronchial wall thickness, and %CSA, yielding a sensitivity of 75% and specificity of 80%. Moreover, the same research team demonstrated the feasibility of this method in determining whether patients with COPD should undergo right heart catheterization. Besides, Jo et al. (67) suggested that %CSA measurement and pulmonary small vessel changes have the theoretical potential for useful diagnostic applications aimed at early-stage assessment of COPD with pulmonary hypertension.

In addition, COPD patients with emphysema and functional small-airway disorders may have a correlation between the total pulmonary vascular volume (TPVV), as measured by CT, and exercise-induced dyspnea symptoms. A recent investigation found that smokers with only minor/mild emphysema exposed to cigarette smoke and presenting with pulmonary vascular attenuation necessitated more ventilation during exercise, leading to increased dyspnea and unpleasant respiratory sensations. Specifically, the development of emphysema and functional small-airway diseases directly lead to decreased vascularization and smaller pulmonary blood vessels in COPD (68).

Incidental interstitial lung abnormality (ILA) in CT
Incidental ILA is defined as the presence of over 5% of
CT assessment of extrapulmonary disease

COPD progression is associated with comorbidities that share common pathophysiological pathways. Although CT scans of the chest cannot systematically assess all comorbidities, they can be useful in evaluating the extrapulmonary presentation of these diseases (81). Mortality from heart disease in COPD patients surpasses that associated with respiratory failure (82). Ventricular morphometry estimates that have been derived from conventional chest CT plain scanning show strong associations with echocardiography and magnetic resonance imaging findings relating to both structural and functional data (83). Another study utilized the COPDGene cohort consisting of 3,436 individuals with moderate-to-severe COPD. Findings revealed an increase in the sphericity of both the upper-right and left ventricles, corresponding to the progression of disease severity (84). Kim et al. have also found that airflow obstruction, which is a
primary characteristic of COPD, is associated with higher prevalence, range, and severity of coronary atherosclerosis. Therefore, it offers autonomous prognostic insights into cardiac risk (85). Finally, abdominal visceral and subcutaneous adipose tissues were estimated in a cohort of 1,267 COPD participants. The results revealed that individuals with a prior history of myocardial infarction (MI) exhibited a significantly greater mean area of visceral adipose tissue in comparison to those without a history of MI (86).

The presence of skeletal muscle dysfunction and muscle wasting in individuals with COPD suggests the potential for musculoskeletal complications associated with the disease. Though the loss of skeletal muscle mass may occur without a loss of adipose tissue, it could more accurately reflect COPD severity than BMI (87). In a cohort comprising 966 participants from the COPDGene study, the size of the pectoralis major muscle was more strongly correlated to lung function, dyspnea, and a 6MWD than BMI. Notably, even after adjusting for BMI, these correlations remained significant, highlighting the ongoing relevance of the pectoralis major muscle (88). Intercostal muscles play a vital role in alveolar ventilation, especially with increased ventilation demands in COPD patients. Intercostal atrophy is common in COPD patients and is associated with airway obstruction severity, aging, and BMI (89). Although current osteoporosis guidelines do not include smoking or COPD as risk factors, Bon et al. showed that emphysema and high bone resorption markers are independently linked to progressive bone mineral density loss in smokers (90). Another cohort of 3,321 smokers selected from the COPDGene study, 58% of participants had low-volume bone mineral density (vBMD), and 37% showed vertebral fractures (91). A Korean COPD cohort study (92) showed that a decrease in thoracic bone density measured by chest CT was significantly linked to mortality and disease severity in patients. Therefore, for smokers with or without COPD, radiologists are advised to consider possible osteopenia and fractures. A Chinese cohort study found that pectoralis muscle area (PMA) was linked to the severity of COPD airflow obstruction and respiratory outcomes. Lower PMA was noted in patients with mild-to-moderate airflow restriction. Measuring PMA could potentially aid in assessing COPD in the early stages (93).

**QCT in COPD prediction models**

COPD evaluation aims to identify the degree of airflow limitation, assess the impact of the disease on the patient’s overall well-being, and evaluate the potential for future occurrences such as disease exacerbation, hospitalization and death, which can aid clinical decision-making. QCT studies on COPD have developed several models that predict lung function, acute exacerbations, and mortality. Gawlitza et al. (94) established five machine learning-based lung function prediction models by extracting QCT parameters (e.g., mean lung density, total lung volume, volume of low-attenuation area, full width at half maximum, and the difference between the inspiratory and expiratory phases) for 75 participants. Results of this analysis indicate that pulmonary function values of COPD patients can be predicted based on QCT parameters with a reasonable degree of accuracy. González et al. (95) demonstrated that direct training of convolutional neural networks with CT imaging data can identify COPD patients among smokers and predict acute respiratory diseases and mortality. Nonetheless, this approach has high computational costs and memory requirements, which surpasses the processing capacity of current graphics processing units when handling massive datasets. Cho et al. (96) examined the use of radiomics to predict mortality in COPD patients. They derived imaging features from four indicators (emphysema, airway remodeling, pulmonary vascular disease, and air trapping) on chest CT, and used least absolute shrinkage and selection operator (LASSO) and Cox regression to choose five vital features as independent predictors of mortality in COPD patients.

Currently, quantitative imaging prediction models for COPD heavily rely on parameters limited to lung parenchyma or airways and lack close connections with clinical parameters, leading to potential biases. The extensive collection of CT images from a substantial number of clinically and spirometrically stable cases in the COPD cohort offers valuable insights into the underlying disease mechanisms and processes. Future research may investigate the potential of different parameter types and their interactions in predicting COPD outcomes to enhance the accuracy of predictive evaluation models.

**Conclusions**

COPD, a progressive respiratory condition, affects millions worldwide. Cohort studies that investigate the disease mechanisms and effective interventions require accurate and reliable measurements of lung morphology and physiology. These major COPD cohorts around the world are pre-exploratory and well-designed, focusing on smokers with
respiratory symptoms, early disease recognition, smokers with mild interstitial abnormalities, risk assessment of acute exacerbations, and extrapulmonary comorbidities. In addition to statistics on score of life quality, breathlessness, physical performance, exacerbation, reduced lung function, and mortality, QCT is a non-invasive imaging technique that enables precise measurements of lung density, volume, and airway dimensions, and supplements important and objective evidence for disease risk assessment in populations at risk for early disease or with identified early stages of COPD. QCT may offer several advantages over traditional pulmonary function tests, including the ability to differentiate between various types of COPD and to monitor disease progression over time. As a result, QCT may become an important tool to help optimize the diagnosis and treatment of COPD (Figure 4).

Future research will also prioritize the investigation of emphysema and small airway disease phenotypes using imaging techniques. This will enhance our comprehension of the intricate interplay between structural, functional, and biological alterations that manifest in individuals with COPD. Moreover, the development of automated QCT...
analysis tools can improve the efficiency and reproducibility of measurements, facilitating large-scale studies across different populations. Overall, QCT represents a valuable tool for investigating COPD and has the potential to enhance medical decision-making and optimize patient care (97).

However, the use of QCT in clinical settings is currently not widespread, possibly due to technical barriers, high costs, and challenges. The lack of image analysis methods and support for equipment poses a major obstacle, with numerous medical institutions and clinicians struggle to allocate the necessary resources and time to engage in QCT. Additionally, variations in manufacturers and devices can affect the reliability and comparability of QCT results. Despite the significant value of QCT in COPD research, promoting its application requires standardizing the technology, improving cost-effectiveness, and conducting further research and implementation. Future research should focus on developing and standardizing QCT technology, gathering clinical evidence, conducting cost-effectiveness analyses, providing education and training, and offering policy support and insurance coverage. These efforts will advance the use of QCT in COPD management, leading to more accurate and personalized diagnosis and treatment.

**Acknowledgments**

The authors sincerely acknowledge the contributions to this review of Ms. Jiazhen Zhu from Ningbo No.2 Hospital.

**Funding:** This work was supported by the Zhejiang Provincial Natural Science Foundation of China (No. LTY23H010001), the Zhejiang Provincial Medical Scientific Research Foundation of China (Nos. 2022KY1125 and 2023KY280), the Shanghai Science and Technology Innovation Fund of China (No. 20Y11902600), the Ningbo Clinical Research Center for Medical Imaging of China (No. 2021L003), the Ningbo Clinical Research Center for Respiratory System Disease of China (No. 2022L004), and the NINGBO Leading Medical & Health Discipline of China (No. 2022-S02).

**Footnote**

**References**


**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amergroups.com/article/view/10.21037/jtd-23-1421/coif). EP serves as an unpaid Editorial Board Member of *Journal of Thoracic Disease* from February 2023 to January 2025. The other authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
2020;41:375-81.


